Literature DB >> 15864309

Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells.

Robert J Binder1, Pramod K Srivastava.   

Abstract

The form in which antigens are transferred from cancer cells or infected cells to antigen-presenting cells as a part of the process of priming CD8(+) T cells has been a longstanding unresolved issue. Intact proteins or protein fragments in the form of free peptides or peptides chaperoned by heat-shock protein are possible sources of antigen. We address this here using beta-galactosidase and ovalbumin. Immunization with cell lysates containing intact proteins and heat-shock protein-peptide complexes or with cell lysates depleted of either component demonstrated that protein fragments chaperoned by heat-shock protein and not intact protein were the necessary and sufficient source of antigen transferred to antigen-presenting cells for priming CD8(+) T cell responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864309     DOI: 10.1038/ni1201

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  85 in total

1.  Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells.

Authors:  Takashi Imai; Yu Kato; Chiaki Kajiwara; Shusaku Mizukami; Ikuo Ishige; Tomoko Ichiyanagi; Masaki Hikida; Ji-Yang Wang; Heiichiro Udono
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  Gp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa.

Authors:  Natasa Strbo; Monica Vaccari; Savita Pahwa; Michael A Kolber; Eva Fisher; Louis Gonzalez; Melvin N Doster; Anna Hryniewicz; Barbara K Felber; George N Pavlakis; Genoveffa Franchini; Eckhard R Podack
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

3.  An invariant road to cross-presentation.

Authors:  Fei Duan; Pramod K Srivastava
Journal:  Nat Immunol       Date:  2012-02-16       Impact factor: 25.606

4.  HIV-1 protease has a genetic T-cell adjuvant effect which is negatively regulated by proteolytic activity.

Authors:  Kwang Soon Kim; Dong Bin Jin; So Shin Ahn; Ki Seok Park; Sang Hwan Seo; You Suk Suh; Young Chul Sung
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

5.  Identification of potential HLA class I and class II epitope precursors associated with heat shock protein 70 (HSPA).

Authors:  Pawel Stocki; Nicholas J Morris; Christian Preisinger; Xiao N Wang; Walter Kolch; Gabriele Multhoff; Anne M Dickinson
Journal:  Cell Stress Chaperones       Date:  2010-04-01       Impact factor: 3.667

6.  Dendritic cell targeted vaccines: Recent progresses and challenges.

Authors:  Pengfei Chen; Xinsheng Liu; Yuefeng Sun; Peng Zhou; Yonglu Wang; Yongguang Zhang
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

7.  Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice.

Authors:  Robert G Newman; Michael J Dee; Thomas R Malek; Eckhard R Podack; Robert B Levy
Journal:  Blood       Date:  2014-03-31       Impact factor: 22.113

8.  Establishment of tumor-associated immunity requires interaction of heat shock proteins with CD91.

Authors:  Yu Jerry Zhou; Michelle Nicole Messmer; Robert Julian Binder
Journal:  Cancer Immunol Res       Date:  2013-12-31       Impact factor: 11.151

9.  Peptidases released by necrotic cells control CD8+ T cell cross-priming.

Authors:  Jaba Gamrekelashvili; Tamar Kapanadze; Miaojun Han; Josef Wissing; Chi Ma; Lothar Jaensch; Michael P Manns; Todd Armstrong; Elizabeth Jaffee; Ayla O White; Deborah E Citrin; Firouzeh Korangy; Tim F Greten
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

Review 10.  Functions of heat shock proteins in pathways of the innate and adaptive immune system.

Authors:  Robert Julian Binder
Journal:  J Immunol       Date:  2014-12-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.